Antifungal and antiparasitic activities of lactoferrin

Anti-Infective Agents in Medicinal Chemistry

Volumn 8, Issue 2, 2009, Pages 114-127

  Leboffe, Loris ^a   Giansanti, Francesco ^b   Antonini, Giovanni ^a  

^a ROMA TRE UNIVERSITY   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Antifungal; Antimicrobial peptides; Antiparasitic; Iron; Lactoferrin; Mycosis; Natural immunity; Parasitic diseases

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; KALIOCIN 1; LACTOFERRICIN; LACTOFERRICIN B; LACTOFERRICIN[17-31]; LACTOFERRICIN[20-25]; LACTOFERRIN; LACTOFERRIN AMPIN[265-284]; LACTOFERRIN PEP; LACTOFERRIN[1-11]; LACTOFERRIN[21-31]; PEPSIN HYDROLYSATE; PEPTIDE 2; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; BREAST MILK; CANDIDA ALBICANS; CLINICAL TRIAL; CONCENTRATION RESPONSE; DERMATOMYCOSIS; DRUG EFFICACY; DRUG POTENTIATION; ENTAMOEBA HISTOLYTICA; FUNGUS GROWTH; GIARDIA LAMBLIA; HOST RESISTANCE; HUMAN; HYPOSALIVATION; IC 50; IMMUNE RESPONSE; IRON BINDING CAPACITY; IRON OVERLOAD; IRON TRANSPORT; MYCOSIS; NONHUMAN; PLASMODIUM FALCIPARUM; THRUSH; TOXOPLASMA GONDII; TOXOPLASMOSIS; TRYPANOSOMA; UPREGULATION;

EID: 67651120180     PISSN: 18715214     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152109787846105     Document Type: Article

References (127)

1. Legrand, D.; Pierce, A.; Elass, E.; Carpentier, M.; Mariller, C.; Mazurier. Lactoferrin structure and functions. J. Adv. Exp. Med. Biol., 2008, 606, 163-94.
2. Reiter, B.; Oram J.D.: Group N Streptococcal phage lysin. J. Gen. Microbiol., 1963, 32, 29-32.
3. Masson, P. L., Heremans, J. F., Prignot, J. J., Wauters, G. Immunohistochemical localization and bacteriostatic properties of an iron-binding protein from bronchial mucus. Thorax, 1966, 21, 538-44
4. Valenti, P.; Antonini, G. Lactoferrin: an important host defence against microbial and viral attack. Cell Mol. Life Sci., 2005, 62, 2576-87.
5. Jenssen, H.; Hancock, R.E.W. Antimicrobial properties of lactoferrin Biochimie, 2008 [Epub ahead of print] (Doi: doi:10.1016/ j.biochi.2008.05.015)
6. Sullivan, D.J.; Moran, G.P.; Pinjon, E.; Al-Mosaid, A.; Stokes, C.; Vaughan, C.; Coleman, D.C. Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res., 2004, 4, 369-76.
7. Van den Bossche, H.; Marichal, P.; Le Jeune, L.; Coene, M.C.; Gorrens, J.; Cools, W. Effects of itraconazole on cytochrome P-450-dependent sterol 14 α-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob. Agents Chemother., 1993, 37, 2101-5.
8. Onishi, J.; Meinz, M.; Thompson, J.; Curotto, J.; Dreikorn, S.; Rosenbach, M.; Douglas, C.; Abruzzo, G.; Flattery, A.; Kong, L.; Cabello, A.; Vicente, F.; Pelaez, F.; Diez, M.T.; Martin, I.; Bills, G.; Giacobbe, R.; Dombrowski, A.; Schwartz, R.; Morris, S.; Harris, G.; Tsipouras, A.; Wilson, K.; Kurtz, M.B. Discovery of novel antifungal (1,3)-β-D-glucan synthase inhibitors. Antimicrob. Agents Chemother., 2000, 44, 368-77.
9. Tanida, T.; Okamoto, T.; Ueta, E.; Yamamoto, T.; Osaki, T. Antimicrobial peptides enhance the Candidacidal activity of antifungal drugs by promoting the efflux of ATP from Candida cells. J. Antimicrob. Chemother., 2006, 57, 94-103.
10. Lockhart, S. R.; Joly, S.; Vargas, K.; Swails-Wenger, J.; Enger, L.; Soll, D. R. Natural defenses against Candida colonization breakdown in the oral cavities of the elderly. J. Dent. Res., 1999, 78, 857-68.
11. Meitner, S. W.; Bowen, W. H.; Haidaris C. G. Oral and esophageal Candida albicans infection in hyposalivatory rats. Infect. Immun., 1990, 58, 2228-36.
12. Odds, F. C. Candidiosis of the oropharynx, In Candida and candidosis: a review and bibliography. Bailliere Tindale, London, United Kingdom, 1988; pp. 117-23.
13. Jorge, A. O.; Totti, M. A.; de Almeida O. P.; Scully C. Effect of sialoadenectomy on the carriage of Candida albicans in the mouths of rats. J. Oral Pathol. Med., 1993, 22, 138-40.
14. Allen, C. M. Animal models of oral candidiasis. A review. Oral Surg. Oral Med. Oral Pathol., 1994, 78, 216-21.
15. Samaranayake, Y. H.; Samaranayake, L. P. Experimental oral candidiasis in animal models. Clin. Microbiol. Rev., 2001, 14, 398-492.
16. Oppenheim, F. G.; T. Xu, F. M.; McMillian, S. M.; Levitz, R. D.; Diamond, G. D.; Offner, Troxler R. F. Histatins, a novel family of histidinerich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J. Biol. Chem., 1988, 263, 7472-77.
17. Pollock, J. J.; Denepitiya, L.; Mackay, B. J.; Iacona, V. J. Fungistatic and fungicidal activity of human parotid salivary histidinerich polypeptides on Candida albicans. Infect. Immun., 1984, 44, 702-7.
18. Takakura, N.; Wakabayashi, H.; Ishibashi, H.; Yamauchi K.; Teraguchi, S.; Tamura, Y.; Yamaguchi, H.; Abe S. Oral Lactoferrin Treatment of Experimental Oral Candidiasis in Mice. Antimicrob. Agents Chemother., 2003, 47(8), 2619-23.
19. Tanida, T.; Okamoto, T.; Okamoto, A.; Wang, H.; Hamada, T.; Ueta, E.; Osaki, T. J. Decreased excretion of antimicrobial proteins and peptides in saliva of patients with oral candidiasis. Oral Pathol. Med., 2003, 32, 586-94.
20. Cumming, C.L.; White, C.; Blackwell, C.L.; Wray, D. Denture stomatitis in the elderly. Oral Microbiol. Immunol., 1990, 5, 82-5.
21. Wilkieson, C.; Samaranayake, L.P.; MacFarlane, T.W.; Lamey, P.J. Oral candidosis in elderly in longterm hospital care. J. Oral Pathol. Med., 1991, 20, 13-6.
22. Bullen, J. J.; Rogers, H. J.; Spalding, P. B.; Ward, C. G. Natural resistance, iron and infection: a challenge for clinical medicine. J. Med. Microbiol., 2006, 55, 251-8.
23. Ramanan, N.; Wang, T. A high-affinity iron permease essential for Candida albicans virulence. Science, 2000, 288, 1062-4.
24. Artis, W. M.; Fountain, J. A.; Delcher, H. K.; Jones, H. E. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes, 1982, 31, 1109-14.
25. Sutcliffe, M. C.; Savage, A. M.; Alford, R. H. Transferrin dependent growth inhibition of yeast-phase Histoplasma capsulatum by human serum and lymph. J. Infect. Dis., 1980, 142, 209-19.
26. Clément, M.; Tremblay, J.; Lange, M.; Thibodeau, J.; Belhumeur, P. Whey-derived free fatty acids suppress the germination of Candida albicans in vitro. FEMS Yeast Res., 2007, 7, 276-85.
27. Andersson, Y.; Lindquist, S.; Lagerqvist, C.; Hernell, O. Lactoferrin is responsible for the fungistatic effect of human milk. Early Hum. Dev., 2000, 59, 95-105
28. Masson, P.L.; Heremans, J.F. Lactoferrin in milk from different species. Comp. Biochem. Physiol., 1971, 39B, 119-29.
29. Lonnerdal, B.; Keen, C.L.; Hurley, L.S.; Fisher, G.L. Developmental changes in the composition of beagle dog milk. Am. J. Vet. Res., 1981, 42, 662-6.
30. King, R. D.; Kahn, H. A.; Foye, J. C.; Greenberg, J. H.; Jones, H. E. Transferrin, iron and dermatophytes. 1. Serum dermatophyte inhibitory component definitively identified as unsaturated transferrin. J. Lab. Clin. Med., 1975, 86, 204-12.
31. Boelaert, J. R.; de Locht, M.; van Cutsem, J.; Kerrels, V.; Cantinieaux, B.; Verdonck, A.; van Landuyt, H. W.; Schneider, Y.J. Mucormycosis during deferoxamine therapy is a siderophore mediated infection: in-vitro and in-vivo animal studies. J. Clin. Invest., 1993, 91, 1979-76.
32. Hissen, A.H.T.; Chow, J. M. T.; Pinto, L. J.; Moore M. M. Survival of Aspergillus fumigatus in serum involves removal of iron from transferrin: the role of siderophores. Infect. Immun., 2004, 72, 1402-8.
33. Valenti, P.; Visca, P.; Antonini, G.; Orsi, N. Interaction between lactoferrin and ovotransferrin and Candida cells. FEMS Microbiol. Lett., 1986, 33, 271-5.
34. Reiter, B.; Brock, J.H.; Steel E.D. Inhibition of Escherichia coli by bovine colostrum and post-colostral milk. II. The bacteriostatic effect of lactoferrin on a serum susceptible and serum resistant strain of E. coli. Immunology, 1975, 28, 83-95.
35. Xu, Y. Y.; Samaranayake, Y. H.; Samaranayake, L. P.; Nikawa, H. In vitro susceptibility of Candida species to lactoferrin. Med. Mycol., 1999, 37, 35-41.
36. Viejo-Díaz, M.; Andrès, M. T. S.; Fierro J. F. Modulation of In vitro fungicidal activity of human lactoferrin against Candida albicans by extracellular cation concentration and target cell metabolic activity. Antimicrob. Agents Chemother., 2004, 48, 1242-8.
37. Bellamy, W.R., Wakabayashi, H., Takase, M., Kawase, K., Shimamura, S., Tomita, M.: Role of cell-binding in the antibacterial mechanism of lactoferricin B. J. Appl. Bacteriol., 1993, 75, 478-84.
38. Bellamy, W; Wakabayashi, H.; Takase, M.; Kawase, K.; Shimamura, S.; Tomita, M. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med. Microbiol. Immunol., 1993, 182, 97-105.
39. Lupetti, A.; Paulusma-Annema, A.; Welling, M. M.; Senesi, S.; Van Dissel, J. T.; Nibbering P. H. Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob. Agents Chemother., 2000, 44, 3257-63.
40. Lupetti, A.; Brouwer, C.P.; Bogaards, S.J.; Welling, M.M.; de Heer, E.; Campa, M.; van Dissel, J.T.; Friesen, R.H.; Nibbering, P.H. Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection. J. Infect. Dis., 2007, 196, 1416-24.
41. Ueta, E.; Tanida, T.; Osaki, T. A novel bovine lactoferrin peptide, FKCRRWQWRM, suppresses Candida cell growth and activates neutrophils. J. Pept. Res., 2001, 57, 240-9.
42. Wakabayashi, H.; Abe, S.; Teraguchi, S.; Hayasawa, H.; Yamaguchi, H. Inhibition of hyphal growth of azole resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compounds. Antimicrob. Agents Chemoteher., 1998, 42, 1587-91.
43. Kretschmar, M.; Hube, B.; Bertsch, T.; Sanglard, D.; Merker, R.; Schröder, M.; Hof, H.; Nichterlein, T. Tubes and proteinase activity contribute to virulence of Candida albicans in murine peritonitis. Infect. Immun., 1999, 67, 637-42.
44. Fratti, R.A.; Belanger, P.H.; Sanati, H.; Ghannoum, M.A. The effect of the new triazole, voriconazole (UK-109,496), on the interactions of Candida albicans and Candida krusei with endothelial cells. J. Chemother., 1998, 10, 7-16.
45. López-Ribot, J. L.; Vespa, M.N,; Chaffin, W.L. Adherence of Candida albicans germ tubes to murine tissues in an ex vivo assay. Can. J. Microbiol., 1994, 40, 77-81.
46. Odds, F.C. Pathogenesis of Candida infections. J. Am. Acad. Dermatol., 1994, 31, S2-5.
47. Munoz, A.; Marcos, J.F. Activity and mode of action against fungal phytopathogens of bovine lactoferricin-derived peptides. J. Appl. Microbiol., 2006, 101, 1199-207.
48. Farnaud, S.; Evans R. W. Lactoferrin: a multifunctional protein with antimicrobial properties. Mol. Immunol., 2003, 40, 395-405.
49. Viejo-Dìaz, M.; Andrès M. T. S.; Fierro. J. F. Different anticandida activities of two human lactoferrin-derived peptides, Lfpep and kaliocin-1. Antimicrob. Agents Chemother., 2005, 49, 2583-88.
50. Lupetti, A.; van Dissel, J. T.; Brouwer, C. P. J. M.; Nibbering P. H. Human antimicrobial peptides' antifungal activity against Aspergillus fumigatus. Eur. J. Clin. Microbiol. Infect. Dis., 2008, 27, 1125-9.
51. Lupetti, A.; Paulusma-Annema, A.; Senesi, S.; Campa, M.; Van Dissel, J.T.; Nibbering, P.H. Internal thiols and reactive oxygen species in candidacidal activity exerted by an N-terminal peptide of human lactoferrin. Antimicrob. Agents. Chemother., 2002, 46, 1634-9.
52. Lupetti, A.; Brouwer, C.P.; Dogterom-Ballering, H.E.; Senesi, S.; Campa, M.; Van Dissel, J.T.; Nibbering, P.H. Release of calcium from intracellular stores and subsequent uptake by mitochondria are essential for the candidacidal activity of an N-terminal peptide of human lactoferrin. J. Antimicrob. Chemother., 2004, 54, 603-8.
53. Van der Kraan, M. I. A.; van der Made, C.; Nazmi, K.; van't Hof, W.; Groenink, J.; Veerman, E. C. I.; Bolscher, J. G. M.; Nieuw, A. V. Amerongen Effect of amino acid substitutions on the candidacidal activity of LFampin 265-284 Peptides. Peptides, 2005, 26, 2093-7.
54. Haney, E. F.; Nazmi, K.; Lau F.; Bolscher, J.G.M.; Vogel H. Biochimie, 2008 Epub ahead of print (DOI: doi:10.1016/j.biochi.2008.04.013)
55. Chen, H.L.; Yen, C.C.; Lu, C.Y.; Yu, C.H.; Chen, C.M. Synthetic Porcine Lactoferricin with a 20-Residue Peptide Exhibits Antimicrobial Activity against Escherichia coli, Staphylococcus aureus, and Candida albicans. J. Agric. Food Chem., 2006, 54, 3277-82.
56. Wakabayashi, H.; Abe, S.; Okutomi, T.; Tansho, S.; Kawase, K.; Yamaguchi, H. Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol. Immunol., 1996, 40, 821-5.
57. Kuipers, M. E.; De Vries, H. G.; Eikelboom, M. C.; Meijer, D. K. F.; Swart, P. J. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against Clinical Candida Isolates. Antimicrob. Agents Chemother., 1999, 43, 2635-41.
58. Naidu, A.S.; Fowler, R.S.; Martinez, C.; Chen, J.; Tulpinski, J. Activated lactoferrin and fluconazole synergism against Candida albicans and Candida glabrata vaginal isolates. J. Reprod. Med., 2004, 49, 800-7.
59. Wakabayashi, H.; Okutomi, T.; Abe, S.; Hayasawa, H.; Tomita, M.; Yamaguchi, H. Enhanced anti-Candida activity of neutrophils and azole antifungal agents in the presence of lactoferrin-related compounds. Adv. Exp. Med. Biol., 1998, 443, 229-37.
60. Lupetti, A.; Paulusma-Annema, A.; Welling, M.M.; Dogterom-Ballering, H.; Brouwer, C.P.; Senesi, S.; Van Dissel, J.T.; Nibbering, P.H. Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Antimicrob. Agents Chemother., 2003, 47, 262-7.
61. Okutomi, T.; Abe, S.; Tansho, S.; Wakabayashi, H.; Kawase, K.; Yamaguchi, H. Augmented inhibition of growth of Candida albicans by neutrophils in the presence of lactoferrin. FEMS Immunol. Med. Microbiol., 1997, 18, 105-12.
62. Kullberg, B. J.; Netea, M. G.; Vonk, A. G.; van der Meer, J. W. Modulation of neutrophil functions in host defense against disseminated Candida albicans infection in mice. FEMS Immunol. Med. Microbiol., 1999, 26, 299-307.
63. Tanida, T.; Rao, F.; Hamada, T.; Ueta, E. Osaki, T. Lactoferrin peptide increases the survival of Candida albicans-inoculated mice by upregulating neutrophil and macrophage functions, especially in combination with amphotericin B and granulocyte-macrophage colony-stimulating factor. Infect. Immun., 2001, 69, 3883-90.
64. Wakabayashi, H.; Uchida, K.; Yamauchi, K.; Teraguchi, S.; Hayasawa, H.; Yamaguchi, H. In: Lactoferrin: Structure, Function and Applications. Shimazaki, K.; Tsuda, H.; Tomita, M.; Kuwata, T.; Perraudin, J.P. Eds. Amsterdam: Elsevier, 2000; pp 203-8.
65. Wakabayashi, H.; Uchida, K.; Yamauchi, K.; Teraguchi, S.; Hayasawa, H.; Yamaguchi, H. Lactoferrin given in food facilitates dermatophytosis cure in guinea pig models. J. Antimicrob. Chemother., 2000, 46, 595-601.
66. Wakabayashi, H.; Takakura, N.; Yamauchi, K.; Teraguchi, S.; Uchida, K.; Yamaguchi, H.; Tamura, Y. Effect of lactoferrin feeding on the host antifungal response in guinea-pigs infected or immunised with Trichophyton mentagrophytes. J. Med. Microbiol., 2002, 51, 844-50.
67. Wakabayashi, H.; Takakura, N.; Teraguchi, S.; Tamura, Y. Lactoferrin feeding augments peritoneal macrophage activities in mice intraperitoneally injected with inactivated Candida albicans. Microbiol. Immunol., 2003, 47, 37-43.
68. Fischer, R.; Debbabi, H.; Dubarry, M.; Boyaka P.; Tomè, D. Regulation of physiological and pathological Th1 and Th2 responses by lactoferrin. Biochem. Cell. Biol., 2006, 84, 303-22.
69. Takakura, N.; Wakabayashi, H.; Ishibashi, H.; Yamauchi, K.; Teraguchi, S.; Tamura, Y.; Yamaguchi, H.; Abe, S. Effect of orally administered bovine lactoferrin on the immune response in the oral candidiasis murine model. J. Med. Microbiol., 2004, 54, 495-500.
70. Teraguchi, S.; Wakabayashi, H.; Kuwata, H.; Yamauchi, K.; Tamura, Y. Protection against infections by oral lactoferrin: Evaluation in animal models. BioMetals, 2004, 17, 231-4.
71. Okamoto, T.; Tanida, T.; Wei, B.; Ueta, E.; Yamamoto, T.; Osaki T. Regulation of fungal infection by a combination of amphotericin b and peptide 2, a lactoferrin peptide that activates neutrophils clinical and diagnostic laboratory. Immunology, 2004, 11, 1111-9.
72. Yamauchi, K.; Hiruma, M.; Yamazaki, N. In: Clinical evaluation of orally administered bovine lactoferrin for treatment of tinea pedis. Shimazaki K, Tsuda H, Tomita M, Kuwata T, Perraudin J-P Eds. Lactoferrin: Structure, Function and Applications. Elsevier: Amsterdam, 2000; pp. 377-81,
73. Yamauchi, K.; Hiruma, M.; Yamazaki, N.; Wakabayashi, H.; Kuwata, H.; Teraguchi, S.; Hayasawa, H.; Suegara, N.; Yamaguchi, H. Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study. Mycoses, 2000, 43, 197-202.
74. Abe, S.; Okutomi, T.; Tansho, S.; Ishibashi, H.; Wakabayashi, H.; Teraguchi, S.; Hayasawa, H.; Yamaguchi, H. Shimazaki, K.; Tsuda, H.; Tomita, M.; Kuwata, T.; Perraudin, J. P. Eds., In: Proceedings of the 4th International Conference on Lactoferrin: structure, function and applications. Elsevier Science B.V., Amsterdam, The Netherlands, 2000.
75. Masci, J. R. Complete response of severe, refractory oral candidiasis to mouthwash containing lactoferrin and lysozyme. AIDS, 2000, 14, 2403-4.
76. Kuipers, M. E.; Heegsma, J.; Bakker, H. I.; Meijer, D. K. F.; Swart, P. J.; Frijlink, E. W.; Eissens, A. C.; de Vries-Hospers, H. G.; van den Berg J. J. M. Design and fungicidal activity of mucoadhesive lactoferrin tablets for the treatment of oropharyngeal candidosis. Drug Deliv., 2002, 9, 31-8.
77. Gilles, H.-G. Protozoal diseases, Arnold: New York, 1999.
78. Loo, V.G.; Lalonde, R.G. Role of iron in intracellular growth of Trypanosoma cruzi. Infect. Immun., 1984, 45, 726-30.
79. Chaudhri, M.; Steverding, D.; Kittelberger, S.; Tjia, S.; Overath, P. Expression of glycosylphosphatidylinositol-anchored Trypanosoma brucei transferrin-binding protein complex in insect cells. Proc. Natl Acad. Sci. USA, 1994, 91, 6443-47.
80. Ligtenberg, M.J.L.; Bitter, W.; Kieft, R.; Steverding, D.; Janssen, H.; Calafat, J.; Borst, P. Reconstitution of a surface transferring binding complex in insect form Trypanosoma brucei. EMBO J., 1994, 13, 2565-73.
81. Steverding, D.; Stierhof, Y.D.; Chaudhri, M.; Ligtenberg, M.; Schell, D.; Beck-Sickinger, A.G.; Overath, P. ESAG6 and 7 products of Trypanosoma brucei form a transferrin binding protein complex. Eur. J. Cell Biol., 1994, 64, 78-87.
82. Bitter, W.; Gerrits, H.; Kieft, R.; Borst, P. The role of transferrinreceptor variation in the host range of Trypanosoma brucei. Nature, 1998, 391, 499-502.
83. Van Luenen, H.G.A.M.; Kieft, R.; Mussmann, R.; Engstler, M.; Riet, B.; Borst, P. Trypanosomes change their transferrin receptor expression to allow effective uptake of host transferring. Mol. Microbiol., 2005, 58, 151-65.
84. Steverding, D.; Stierhof, Y.D.; Fuchs, H.; Tauber, R.; Overath, P. Transferrin-binding protein complex is the receptor for transferrin uptake in Trypanosoma brucei. J. Cell Biol., 1995, 131, 1173-82.
85. Wilson, M.E.; Lewis, T.S.; Miller, M.A.; McCormick, M.L.; Britigan, B.E. Leishmania chagasi: uptake of iron bound to lactoferrin or transferrin requires an iron reductase. Exp. Parasitol., 2002, 100, 196-207.
86. Coombs, G.H.; Mottram, J.C. In Trypanosomiasis and Leishmaniasis: Biology and Control; CAB Intemational: Oxford. 1997; pp. 177-97.
87. Del Nery, E.; Juliano, M.A.; Lima, A.A.; Scharfstein, J.; Juliano, L. Kininogenase activity by the major cysteinyl proteinase (cruzipain) from Trypanosoma cruzi. J. Biol. Chem., 1997, 272, 25713-18.
88. McKerrow, J.H.; Sun, E.; Rosenthal, P.J.; Bouvier, J. The proteases and pathogenicity of parasitic protozoa. Annu. Rev. Microbiol., 1993, 47, 821-53.
89. McKerrow, J.H.; McGrath, M.E.; Engel, J.C. The cysteine protease of Trypanosoma cruzi as a model for antiparasite drug design. Parasitol. Today, 1995, 11, 279-82.
90. McKerrow, J.H. Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. Int. J. Parasitol., 1999, 29, 833-37.
91. Caffrey, C.R.; Scory, S.; Steverding, D. Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy. Curr. Drug. Targets, 2000, 1, 155-62.
92. Sajid, M.; McKerrow, J.H. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol., 2002, 120, 1-21.
93. Mottram, J.C.; Coombs, G.H.; Alexander, J. Cysteine peptidases as virulence factors of Leishmania. Curr. Opin. Microbiol., 2004, 7, 375-81.
94. Katunuma, N.; Ohashi, A.; Sano, E.; Murata, E.; Shiota, H.; Yamamoto, K.; Majima, E.; Le, Q.T. New cysteine protease inhibitors in physiological secretory fluids and their medical significance. Adv Enzyme Regul., 2003, 43, 393-410.
95. Barrett, A.J.; Rawlings, N.D.; Woessner, J.F. In: Handbook of Proteolytic Enzymes; Academic Press: London and San Diego, 1998.
96. Mackey, Z.B.; O'Brien, T.C.; Greenbaum, D.C.; Blank, R.B.; McKerrow, J.H. A cathepsin B-like protease is required for host protein degradation in Trypanosoma brucei. J. Biol. Chem., 2004, 279, 48426-33.
97. Ohashi, A.; Murata, E.; Yamamoto, K.; Majima, E.; Sano, E.; Le, Q.T.; Katunuma, N. New functions of lactoferrin and beta-casein in mammalian milk as cysteine protease inhibitors. Biochem. Biophys. Res. Commun., 2003, 306, 98-103.
98. Jackson, M.H.; Hutchison, W.M. The prevalence and source of Toxoplasma infection in the environment. Adv. Parasitol., 1989, 28, 55-105.
99. Dubey, J.P. In: Parasitic protozoa; Kreier Ed., 2nd ed. 1993; Vol. 6, pp. 1-158.
100. Evans, R. In: Human toxoplasmosis; Ho-Yen, D.O.; Joss, A.W.L. Eds.; Oxford: Oxford University, 1992; pp. 26-55.
101. Dubey, J.P.; Lindsay, D.S.; Speer, C.A. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin. Microbiol. Rev., 1998, 11, 267-99.
102. Dubey, J.P. Toxoplasmosis: an overview. Southeast Asian. J. Trop. Med. Public Health, 1991, 22, 88-92.
103. Tanaka, T.; Abe, Y.; Kim, W.S.; Xuan, X.; Nagasawa, H.; Igarashi, I.; Kumura, H.; Shimazaki, K. The detection of bovine lactoferrin binding protein on Toxoplasma gondii. J. Vet. Med. Sci., 2003, 65, 1377-80.
104. Dziadek, B.; Dzitko, K.; Dlugonska, H. Toxoplasma gondii binds human lactoferrin but not transferrin. Exp. Parasitol., 2005, 110, 165-7.
105. Dziadek, B.; Dziadek, J.; Dlugonska, H. Identification of Toxoplasma gondii proteins binding human lactoferrin: a new aspect of rhoptry proteins function. Exp. Parasitol., 2007, 115, 277-82.
106. Tanaka, T.; Omata, Y.; Saito, A.; Shimazaki, K.; Igarashi, I.; Suzuki, N. Growth inhibitory effects of bovine lactoferrin to Toxoplasma gondii parasites in murine somatic cells. J. Vet. Med. Sci., 1996, 58, 61-5.
107. Tanaka, T.; Omata, Y.; Narisawa, M.; Saito, A.; Shimazaki, K.; Igarashi, I.; Hirumi, H.; Suzuki, N. Growth inhibitory effect of bovine lactoferrin on Toxoplasma gondii tachyzoites in murine macrophages: role of radical oxygen and inorganic nitrogen oxide in Toxoplasma growth-inhibitory activity. Vet. Parasitol., 1997, 68, 27-33.
108. Tanaka, T.; Omata, Y.; Isamida, T.; Saito, A.; Shimazaki, K.; Yamauchi, K.; Suzuki, N. Growth inhibitory effect of bovine lactoferrin to Toxoplasma gondii tachyzoites in murine macrophages: tyrosine phosphorylation in murine macrophages induced by bovine lactoferrin. J. Vet. Med. Sci., 1998, 60, 369-71.
109. Dzitko, K.; Dziadek, B.; Dziadek, J.; Długońska, H. Toxoplasma gondii: inhibition of the intracellular growth by human lactoferrin. Pol. J. Microbiol., 2007, 56, 25-32.
110. Tanaka, T.; Omata, Y.; Saito A.; Shimazaki K.; Yamauchi K.; Takase M.; Kawase K.; Igarashi K.; Suzuki N. Toxoplasma gondii: parasiticidal effects of bovine lactoferricin against parasites. Exp. Parasitol., 1995, 81, 614-7.
111. Isamida, T.; Tanaka, T.; Omata, Y.; Yamauchi, K.; Shimazaki, K.; Saito, A. Protective effect of lactoferricin against Toxoplasma gondii infection in mice. J. Vet. Med. Sci., 1998, 60, 241-4.
112. Omata, Y.; Satake, M.; Maeda, R.; Saito, A.; Shimazaki, K.; Yamauchi, K.; Uzuka, Y.; Tanabe, S.; Sarashina, T.; Mikami, T. Reduction of the infectivity of Toxoplasma gondii and Eimeria stiedai sporozoites by treatment with bovine lactoferricin. J. Vet. Med. Sci., 2001, 63, 187-90.
113. Fritsch, G.; Sawatzki, G.; Treumer, J.; Jung, A.; Spira, D.T. Plasmodium falciparum: inhibition in vitro with lactoferrin, desferriferrithiocin, and desferricrocin. Exp. Parasitol., 1987, 63, 1-9.
114. Sinnis, P.; Willnow, T.E.; Briones, M.R.; Herz, J.; Nussenzweig, V. Remnant lipoproteins inhibit malaria sporozoite invasion of hepatocytes. J. Exp. Med., 1996, 184, 945-54.
115. Shakibaei, M.; Frevert, U. Dual interaction of the malaria circumsporozoite protein with the low density lipoprotein receptor-related protein (LRP) and heparan sulfate proteoglycans. J. Exp. Med., 1996, 184, 1699-711.
116. Prudhomme, J.G.; Sherman, I.W. A high capacity in vitro assay for measuring the cytoadherence of Plasmodium falciparum-infected erythrocytes. J. Immunol. Methods., 1999, 229, 169-76.
117. Eda, S.; Eda K.; Prudhomme, J.G.; Sherman, I.W. Inhibitory activity of human lactoferrin and its peptide on chondroitin sulfate A-, CD36-, and thrombospondin-mediated cytoadherence of plasmodium falciparum-infected erythrocytes. Blood, 1999, 94, 326-32.
118. Kassim, O.O.; Ako-Anai, K.A.; Torimiro, S.E.; Hollowell, G.P.; Okoye, V.C.; Martin, S.K. Inhibitory factors in breastmilk, maternal and infant sera against in vitro growth of Plasmodium falciparum malaria parasite. J. Trop. Pediatr., 2000, 46, 2-6.
119. Gillin, F.D.; Reiner, D.S.; Wang, C.S. Killing of Giardia lamblia trophozoites by normal human milk. J. Cell Biochem., 1983, 23, 47-56.
120. Turchany, J.M.; Aley, S.B.; Gillin, F.D. Giardicidal activity of lactoferrin and N-terminal peptides. Infect. Immun., 1995, 63, 4550-2.
121. Turchany, J.M.; McCaffery, J.M.; Aley, S.B.; Gillin, F.D. Ultrastructural effects of lactoferrin binding on Giardia lamblia trophozoites. J. Eukaryot. Microbiol., 1997, 44, 68-72.
122. Ochoa, T.J.; Cleary, T.G. Effect of lactoferrin on enteric pathogens. Biochimie 2008, [Epub ahead of print] (DOI: doi:10.1016/ j.biochi.2008.04.006)
123. León-Sicairos, N.; Reyes-López, M.; Canizalez-Román, A.; Bermúdez-Cruz, R.M.; Serrano-Luna, J.; Arroyo, R.; de la Garza, M. Human hololactoferrin: endocytosis and use as an iron source by the parasite Entamoeba histolytica. Microbiology, 2005, 151, 3859-71.
124. Murray, M.J.; Murray, A.; Murray, C.J. The salutary effect of milk on amoebiasis and its reversal by iron. Br. Med. J., 1980, 280, 1351-2.
125. León-Sicairos, N.; López-Soto, F.; Reyes-López, M.; Godínez-Vargas, D.; Ordaz-Pichardo, C.; de la Garza, M. Amoebicidal activity of milk, apo-lactoferrin, sIgA and lysozyme. Clin. Med. Res., 2006, 4, 106-13.
126. León-Sicairos, N.; Reyes-López, M.; Ordaz-Pichardo, C.; de la Garza, M. Microbicidal action of lactoferrin and lactoferricin and their synergistic effect with metronidazole in Entamoeba histolytica. Biochem. Cell Biol., 2006, 84, 327-36.
127. Gifford, J. L.; Huntera H. N.; Vogel, H. J. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell. Mol. Life Sci., 2005, 62, 2588-98.